i2C Solutions, LLC — Department of Defense SBIR Phase I: A15-061

i2C Solutions, LLC — SBIR Phase I award from Department of Defense.

Amount
$99,994
Agency
Department of Defense · Army
Program / Phase
SBIR · Phase I
Topic
A15-061
Solicitation
2015.1
NAICS
Place of performance
CO
Period
2015-09-21 → 2016-04-20

Description

To address the need for improved treatment protocols that can ensure a higher rate of recovery from traumatic eye injury, i2C Solutions in collaboration with Oxygen Emulsion Company (OE Co), LLC, propose to develop a new topical therapy for ocular trauma that derives from a wound-healing technology originally funded by DARPA. The treatment involves application of a liquid peruorodecalin (PFD)/O2 emulsion to the eye. The anticipated therapeutic benefits include up-regulation in collagen I expression, a correlated increase in re-generation of damaged sclera, conjunctiva, corneal epithelium, and ocular adnexa dermal tissues, and acceleration of ocular wound healing.